Santhera Pharmaceuticals Holding AG (SANN) – Strategy, SWOT and Corporate Finance Report

Santhera Pharmaceuticals Holding AG (SANN) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Santhera Pharmaceuticals Holding AG (Santhera) develops and markets novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. The company specifically focuses on the area of neuromuscular and ophthalmological conditions. The company’s lead product candidate, Raxone is developed for the treatment of Leber's hereditary optic neuropathy (LHON) and is approved by the European Marketing Authorization. Raxone is investigated for other diseases such as Duchenne muscular dystrophy and primary progressive multiple sclerosis. Santhera’s pipeline also includes other compounds, namely, omigapil for congenital muscular dystrophies. The company operates through its subsidiaries in Switzerland, Liechtenstein, Germany, Canada, the UK, Italy, the Netherlands, and the US. Santhera is headquartered in Pratteln, Switzerland.

Scope

• Detailed information on Santhera Pharmaceuticals Holding AG required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Santhera Pharmaceuticals Holding AG in the form of a SWOT analysis

• An in-depth view of the business model of Santhera Pharmaceuticals Holding AG including a breakdown and examination of key business segments

• News about Santhera Pharmaceuticals Holding AG, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Santhera Pharmaceuticals Holding AG and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Santhera Pharmaceuticals Holding AG as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Santhera Pharmaceuticals Holding AGs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Triskel Biopharmaceuticals AG

NicOx SA

CARTHAGENETICS SUISSE Sarl

Capricor Therapeutics Inc

Applied Genetic Technologies Corp

Abliva AB

Sarepta Therapeutics Inc

Oncternal Therapeutics

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Santhera Pharmaceuticals Holding AG - Key Facts

Santhera Pharmaceuticals Holding AG - Key Employees

Santhera Pharmaceuticals Holding AG - Key Employee Biographies

Santhera Pharmaceuticals Holding AG - Major Products and Services

Santhera Pharmaceuticals Holding AG - History

Santhera Pharmaceuticals Holding AG - Company Statement

Santhera Pharmaceuticals Holding AG - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Santhera Pharmaceuticals Holding AG - Business Description

Geographical Segment: Asia

Performance

Geographical Segment: Europe

Performance

R&D Overview

Santhera Pharmaceuticals Holding AG - Corporate Strategy

Santhera Pharmaceuticals Holding AG - SWOT Analysis

SWOT Analysis - Overview

Santhera Pharmaceuticals Holding AG - Strengths

Santhera Pharmaceuticals Holding AG - Weaknesses

Santhera Pharmaceuticals Holding AG - Opportunities

Santhera Pharmaceuticals Holding AG - Threats

Santhera Pharmaceuticals Holding AG - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Santhera Pharmaceuticals Holding AG, Recent Deals Summary

Section 5 – Company’s Recent Developments

Jun 06, 2023: Santhera Publishes Agenda for its Annual General Meeting

May 31, 2023: Santhera Publishes Annual Report 2022

Oct 31, 2022: Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update

Jun 30, 2022: Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting

Jun 27, 2022: Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board

Jun 02, 2022: Santhera Announces Preliminary 2022 Half-year Financial Results

Apr 29, 2022: Santhera will Publish its 2021 Annual Report by June 3, 2022, and Hold its Annual General Meeting on June 29, 2022

Mar 11, 2022: Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Santhera Pharmaceuticals Holding AG, Key Facts

Santhera Pharmaceuticals Holding AG, Key Employees

Santhera Pharmaceuticals Holding AG, Key Employee Biographies

Santhera Pharmaceuticals Holding AG, Major Products and Services

Santhera Pharmaceuticals Holding AG, History

Santhera Pharmaceuticals Holding AG, Subsidiaries

Santhera Pharmaceuticals Holding AG, Key Competitors

Santhera Pharmaceuticals Holding AG, Ratios based on current share price

Santhera Pharmaceuticals Holding AG, Annual Ratios

Santhera Pharmaceuticals Holding AG, Annual Ratios (Cont…1)

Santhera Pharmaceuticals Holding AG, Annual Ratios (Cont…2)

Santhera Pharmaceuticals Holding AG, Interim Ratios

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Santhera Pharmaceuticals Holding AG, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Santhera Pharmaceuticals Holding AG, Performance Chart (2018 – 2022)

Santhera Pharmaceuticals Holding AG, Ratio Charts

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports